720 related articles for article (PubMed ID: 30112527)
1. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
2. Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand.
Štarha P; Trávníček Z; Vančo J; Dvořák Z
Molecules; 2018 Feb; 23(2):. PubMed ID: 29443934
[TBL] [Abstract][Full Text] [Related]
3. An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis.
Novohradsky V; Markova L; Kostrhunova H; Trávníček Z; Brabec V; Kasparkova J
Sci Rep; 2019 Sep; 9(1):13327. PubMed ID: 31527683
[TBL] [Abstract][Full Text] [Related]
4. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
5. A photoactivatable Ru (II) complex bearing 2,9-diphenyl-1,10-phenanthroline: A potent chemotherapeutic drug inducing apoptosis in triple negative human breast adenocarcinoma cells.
Mansour N; Bodman-Smith K; Khnayzer RS; Daher CF
Chem Biol Interact; 2021 Feb; 336():109317. PubMed ID: 33197429
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
7. Effect of
Mukherjee A; Acharya S; Purkait K; Chakraborty K; Bhattacharjee A; Mukherjee A
Inorg Chem; 2020 May; 59(9):6581-6594. PubMed ID: 32295347
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Structure and Cytotoxicity of N,N and N,O-Coordinated Ru
Mukherjee A; Koley TS; Chakraborty A; Purkait K; Mukherjee A
Chem Asian J; 2021 Nov; 16(22):3729-3742. PubMed ID: 34549886
[TBL] [Abstract][Full Text] [Related]
9. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
10. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action.
Pavlović M; Nikolić S; Gligorijević N; Dojčinović B; Aranđelović S; Grgurić-Šipka S; Radulović S
J Biol Inorg Chem; 2019 Mar; 24(2):297-310. PubMed ID: 30762123
[TBL] [Abstract][Full Text] [Related]
11. Transport of the Ruthenium Complex [Ru(GA)(dppe)
Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR
Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527
[TBL] [Abstract][Full Text] [Related]
12. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
13. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria-targeted ruthenium complexes can be generated in vitro and in living cells to target triple-negative breast cancer cells by autophagy inhibition.
Zhang GD; Wang MM; Su Y; Fang H; Xue XL; Liu HK; Su Z
J Inorg Biochem; 2024 Jul; 256():112574. PubMed ID: 38677004
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Effects of Ir(III)-2
Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
[TBL] [Abstract][Full Text] [Related]
16. A potential method to improve the in vitro cytotoxicity of half-sandwich Os(ii) complexes against A2780 cells.
Štarha P; Trávníček Z; Herchel R; Jewula P; Dvořák Z
Dalton Trans; 2018 Apr; 47(16):5714-5724. PubMed ID: 29632937
[TBL] [Abstract][Full Text] [Related]
17. Ruthenium(II) complexes as bioorthogonal two-photon photosensitizers for tumour-specific photodynamic therapy against triple-negative breast cancer cells.
Lin M; Zou S; Liao X; Chen Y; Luo D; Ji L; Chao H
Chem Commun (Camb); 2021 May; 57(36):4408-4411. PubMed ID: 33949487
[TBL] [Abstract][Full Text] [Related]
18. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
[TBL] [Abstract][Full Text] [Related]
19. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
20. The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells.
Fayad C; Audi H; Khnayzer RS; Daher CF
J Biol Inorg Chem; 2021 Feb; 26(1):43-55. PubMed ID: 33221954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
